Clinical Trials
13 trialsNCT02613598 2021-12-20
Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma
University of Michigan Rogel Cancer Center
Phase 1 Completed
NCT00381940 2021-03-24
Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT01164709 2019-05-15
Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer
Swiss Cancer Institute
Phase 1 Completed
NCT02208037 2019-01-23
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
National Heart, Lung, and Blood Institute (NHLBI)
Phase 2 Completed
NCT00262860 2016-05-09
Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
University of Rochester
Phase 2 Completed
NCT00082966 2015-12-04
Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00791011 2014-03-05
Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat
Amgen
Phase 1 Completed
NCT00006098 2013-06-18
PS-341 in Treating Patients With Hematologic Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00348985 2013-05-03
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Phase 1 Completed
NCT00004002 2012-11-09
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
NYU Langone Health
Phase 1 Completed
NCT00439361 2012-07-09
Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00237627 2012-05-18
Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Completed
NCT00636311 2010-09-02
A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma
Istituto Clinico Humanitas
Phase 2 Completed